Alpha Tau to Participate in May Investor Conferences
Rhea-AI Summary
Alpha Tau (NASDAQ:DRTS) announced that CFO Raphi Levy will participate in several May 2026 investor conferences, including events hosted by H.C. Wainwright, Rothschild & Co Redburn, and Lytham Partners.
The schedule features fireside chats, presentations, and 1x1 investor meetings in New York and via virtual webcast.
Positive
- None.
Negative
- None.
News Market Reaction – DRTS
In the May 18 session, DRTS declined 3.19%, reflecting a moderate negative market reaction. Argus tracked a trough of -2.8% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 11 | Glioblastoma interim data | Positive | +21.5% | Interim REGAIN trial data with strong local control and complete responses. |
| May 08 | Data call announcement | Positive | +8.4% | Announcement of conference call to discuss interim GBM clinical data. |
| May 08 | Pivotal trial enrollment | Positive | +8.4% | Completion of enrollment in U.S. pivotal cSCC study aiming at FDA approval. |
| May 07 | First pancreatic patient | Positive | +3.4% | First pancreatic cancer patient treated in Italy under feasibility protocol. |
| May 05 | Upcoming AHNS presentation | Positive | -1.9% | Announcement of future podium presentation on Alpha DaRT plus pembrolizumab. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent clinically focused and trial-milestone news often saw positive price reactions, with one noted divergence on a conference presentation announcement.
In the past weeks, Alpha Tau reported several Alpha DaRT® milestones, including 100% local disease control and a 67% complete response rate in early U.S. REGAIN glioblastoma data on May 11, 2026, and completion of enrollment of 88 patients in its U.S. pivotal skin cancer study on May 8, 2026. These updates, plus new pancreatic and head & neck programs, often coincided with positive price moves. Today’s investor conference participation fits into an active outreach phase following these clinical and regulatory developments.
AI-generated analysis. How Rhea-AI works. Not financial advice.
JERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will participate in the following investor conferences in May 2026.
| Event: | H.C. Wainwright 4th Annual BioConnect Investor Conference |
| Format: | Fireside Chat and 1x1 Meetings |
| Date: | Tuesday, May 19, 2026 |
| Time: | 10:30 – 11:00AM ET |
| Location: | New York, NY |
| Event: | Rothschild & Co Redburn Radiopharma Conference 2026 |
| Format: | 1x1 Meetings |
| Date: | Wednesday, May 27, 2026 |
| Location: | New York, NY |
| Event: | Lytham Partners Spring 2026 Investor Conference |
| Format: | Presentation and 1x1 Meetings |
| Date: | Thursday, May 28, 2026 |
| Time: | 9:00AM ET |
| Location: | Virtual - https://app.webinar.net/Ew6XKl4KQ71 |
Mr. Levy will be available for 1x1 investor meetings at all conferences. Please reach out to your H.C. Wainwright, Rothschild, or Lytham Partners representatives to schedule.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact:
